FDA Breakthrough Status for Lilly’s Sofetabart Mipitecan ADC
Indianapolis, January 20, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Indianapolis, January 20, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
